Supra-additive effect with concurrent paclitaxel and cisplatin in vulvar squamous cell carcinoma in vitro.

摘要: The effect of concurrent paclitaxel and cisplatin was tested in vitro 5 vulvar squamous cell carcinoma (SCC) lines (UM-SCV-1A, -2, -4 -7 UT-SCV-3). Chemosensitivity using the 96-well plate clonogenic assay. Paclitaxel concentrations used varied between 0.4 1.6 nM, 0.1 0.9 μg/ml. These drug are clinically achievable. Survival data were fitted to LQ model, area under curve (AUC) value obtained with numerical integration. type interaction determined by comparing AUC ratio 2 drugs survival fraction (SF) alone. With all growth-inhibitory simultaneous at least additive. combination on UM-SCV-1A UT-SCV-3 clearly supra-additive tested, UM-SCV-4 UM-SCV-7 exhibited a increasing concentrations. degree supra-additivity dose-dependent line synergy higher doses. In current study had clear additive or cytotoxic SCC lines, it has been successfully other gynecologic malignancies; therefore also deserves further testing clinical settings advanced-stage carcinoma, which poor prognosis. © 2002 Wiley-Liss, Inc.